Capture of CO2 from medium-scale emission sources

AbstractUntil now, the work done on capture and storage of CO2 has mainly focused on capture and storage of CO2 from fossil fuel fired power plants and other large point sources. Although medium-scale sources of CO2 account for a smaller proportion, their contribution to global CO2 emissions is still substantial and in the range of 10–15% of total global energy related CO2 emissions. The study identifies possible combinations of capture technologies and medium scale combustion installations and assesses these in terms of potential and costs. Although medium-scale capture of CO2 is expected to be more expensive than large-scale capture, it may nevertheless be competitive with alternative methods of abating CO2 from medium-scale sources in some circumstances

Opportunities for CO2 capture through oxygen conducting membranes at medium-scale oxyfuel coal boilers

AbstractEcofys and ECN conducted a study commissioned by the IEA Greenhouse Gas R&D Programme to identify the most suitable combinations of medium-scale CO2 sources (1–100 MWth) and capture technologies, with respect to potential and costs (see parallel paper by Hendriks et al.). An industrial coal-fired Circulating Fluidized Bed (CFB) boiler with oxyfuel combustion and Oxygen Conducting Membranes (OCM) appeared to be an economically attractive combination to capture CO2. This paper describes the principle and economic evaluation of this combination in comparison with a reference coal boiler without CO2 capture, as well as a coal boiler with CO2 capture based on amine scrubbing

Эффективность комбинированных криоконсервантов, содержащих глицерин или 1,2-пропандиол, при замораживании эритроцитов

Исследовали осмотические свойства эритроцитов, замороженных в комбинированных криоконсервантах, содержащих полимерные непроникающие (декстран, полиэтиленгликоль) и проникающие (глицерин, 1,2-пропандиол) криопротекторы. Установлено, что в эритроцитах, замороженных-отогретых в среде с полимерами, отмечается повышение скорости потока ионов Н+ и осмотической хрупкости в среде, содержащей 0,45–0,9% NaCl. Для сохранения осмотических свойств замороженных- отогретых клеток достаточно включить в среду глицерин или 1,2-пропандиол (1,2-ПД) в концентрации 5%. Полученные результаты позволяют предположить, что криопротекторная эффективность комбинированных криоконсервантов, содержащих непроникающие и проникающие криопротекторы, определяется вкладом различных по механизму действия криозащитных компонентов в суммарную защитную эффективность при замораживании и ослаблением постгипертонического стресса на клетки при размораживании.Досліджували осмотичні властивості еритроцитів, заморожених-відігрітих у комбінованих кріоконсервантах, які містять полімерні непроникаючі (декстран, поліетиленгліколь) і проникаючі (гліцерин, 1,2-пропандіол) кріопротектори. Встановлено, що в еритроцитах, заморожених-відігрітих у середовищі з полімерами, визначається зростання швидкості потоку іонів Н+ і осмотичної крихкості в середовищі, яке містить 0,45–0,9% NaCl. Для збереження осмотичних властивостей заморожених- відігрітих клітин достатньо включити в середовище гліцерин або 1,2-пропандіол в концентрації 5%. Отримані результати дозволяють припустити, що кріопротекторна ефективність комбінованих кріоконсервантів, які містять непроникаючі і проникаючі кріопротектори, визначається внеском різноманітних за механізмом дії кріозахисних компонентів у сумарну захисну ефективність при заморожуванні та послабленням постгіпертонічного стресу на клітини при розморожуванні.The osmotic properties of erythrocytes frozen-thawed in combined cryopreservatives, containing polymeric non-penetrating (dextran, polyethylene glycol) and penetrating (glycerol, 1,2-propane diol) cryoprotectants were studied. It was established that in erythrocytes frozen-thawed in the presence of polymers the increasing of H+ ion flow rate and osmotic fragility in the environment with 0.45–0.9% NaCl was observed. It is sufficient to add 5% glycerol or 1,2-propane diol (1,2-PD) to the medium to preserve osmotic properties of frozen-thawed cells. The obtained results enable to suggest that cryoprotective efficiency of combined cryopreservatives, containing non-penetrating and penetrating cryoprotectants is determined both by the contribution of cryoprotective components differing by action mechanism into th

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Mitigation Theme Report: Energy Efficiency : Contribution to the MCA4climate initiative

Striving for energy efficiency means trying to obtain a certain result with a minimum of input (Schipper and Meyers, 1992; Blok, 2007). As energy is used to fulfil human needs, one may define the energy efficiency of an activity as the degree to which given human needs can be fulfilled with a minimum amount of energy. So, energy efficiency improvement can be defined as reducing the energy use per unit of human activity. The energy use per unit of human activity is also called energy intensity. In most cases, energy efficiency measurement is done by measuring energy intensity, but it is important to recognize that it is actually the inverse energy efficiency

Technical Potential for Photovoltaics on Buildings in the EU-27

Accurate knowledge on the technical potential for Building Integrated PhotoVoltaics (BIPV) in the various member states of the European Union is unavailable. To estimate the potential for BIPV we developed a method using readily available statistical data on buildings from European databases. Based on country-specific data on building characteristics and irradiation we estimate the BIPV technical potential in the EU-27 at 951 GWp. Installed it can deliver about 840 TWh of electricity, which is equivalent to more than 22% of the expected European 2030 annual electricity deman

Informed public opinion in the Netherlands: Evaluation of CO2 capture and storage technologies in comparison with other CO2 mitigation options

In this study, 995 respondents in a representative sample of the Dutch general population are set in the situation of policymakers: they are faced with the issue of fulfilling the Dutch demand for energy in 2030 in such a way that emissions of carbon dioxide will be reduced by 50%. In the Information-Choice Questionnaire (ICQ) that was developed for this, respondents evaluated information from experts on seven options for CO2 emission reduction and their consequences. Two CCS options were compared to two energy efficiency options, a wind energy option, a biomass energy option, and a nuclear energy option. Results show that people are not that enthusiastic regarding the two CCS options. These are evaluated 5.3 and 5.9 on average on a scale of 1–10 and not often chosen as one of the three preferred options, but they are also rarely rejected. Most of the other options in the questionnaire were evaluated rather positively, except nuclear energy and the more ambitious efficiency option. Analysis shows that the evaluation of the information regarding consequences moderately influences how options are evaluated overall. The results further indicate that the CCS options are evaluated less positively due to the comparison with other options